Mental Health Clinics in Copperas Cove, TX Accepting Medicare
7 Mental Health Clinics found. Showing 1 - 7
 Senior Insights Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1007 W. Highway 190, Ste B, Copperas Cove, TX 76522 Phone: 254-542-7200 Fax: 866-602-0977 |
Blooming Thoughts Counseling And Wellness, Pllc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2745 Settlement Rd, Copperas Cove, TX 76522 Phone: 254-401-0878 |
House Of Inspiration Residential Services Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 1303 Dixon Cir, Copperas Cove, TX 76522 Phone: 214-723-3688 |
Inbesi Cares Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 710 Martha Dr, Copperas Cove, TX 76522 Phone: 254-680-6933 Fax: 844-910-1883 |
Travail Adaptations Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1216 Duncan Rd, Copperas Cove, TX 76522 Phone: 254-577-4880 |
The Oaks Personal Growth And Counseling Center Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 964 W Highway 190, Suite 10, Copperas Cove, TX 76522 Phone: 254-547-8000 |
Cove Counseling Center Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1007 West Highway 190, Suite B, Copperas Cove, TX 76522 Phone: 254-542-7200 Fax: 866-602-0977 |
News Archive
Nanosys reaches settlement of patent infringement lawsuit against Nanoco Technologies
Nanosys, Inc. today announced it has agreed to settlement terms of a patent infringement lawsuit against Nanoco Technologies Ltd.
New guide may help parents detect body image issues in children
What does your teen see when they look in the mirror? Body image encompasses what a person believes about their outward appearance, how they feel about their body and how they sense and control their movements.
ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients
ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period.
Research finds rise in number of New Hampshire infants diagnosed with NAS
From 2005 to 2015 the number of infants diagnosed with neonatal abstinence syndrome (NAS) in the Granite State increased fivefold, from 52 to 269, according to new research by the Carsey School of Public Policy at the University of New Hampshire.
Study shows engineered SARS-CoV-2 spike protein may be utilized for vaccine development
In a new study available on the preprint server bioRxiv, researchers demonstrate how the conformation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S-protein) can be controlled with the rational construct design, providing a framework for S-protein structure engineering in vaccine/drug development.
› Verified 6 days ago